RaySearch Laboratories AB (publ) announces that McLaren Proton Therapy Center in Flint, Michigan, has placed an order for the treatment planning system RayStation®*.
The McLaren Proton Therapy Center has a long history of proton treatments in the Detroit and eastern Michigan area. The center is the only National Cancer Institute (NCI) - designated comprehensive cancer center in metropolitan Detroit and one of just 51 centers of its kind in the United States. Since 2018, the center's capacity has grown, and they have recently treated their 600th patient.
The RayStation purchase will support the proton therapy program and will include technologies such as deep learning segmentation, image deformation, adaptive planning, and fallback planning, which allows for contingency planning and comparison of modalities to help clinicians select the most appropriate treatment technique. Additionally, the department is slated to become the first in the world to deliver proton therapy to patients with Leo Cancer Care’s upright treatment technology. The partnership between Leo Cancer Care and RaySearch was recently announced in a separate press release.
Vahagn Nazaryan, Ph.D., Executive Director of Radiation Oncology Services & McLaren Proton Therapy Center, says, "We continue to seek out partners who are innovative and offer technology that benefits patients by enhancing the quality of all aspects of their care. This new partnership enhances our patient-focused approach to all that we do.”
Johan Löf, founder and CEO of RaySearch, says: “We look forward to collaborating with the McLaren Proton Center on both conventional proton therapy and exciting new treatment approaches. RaySearch recently announced a partnership with Leo Cancer Care, and the implementation of RayStation in the McLaren center will enable the center to fully utilize this technology."
About McLaren Proton Therapy Center
The McLaren Proton Therapy Center in Flint, Michigan, part of the Karmanos Cancer Institute at McLaren Flint, is the largest proton center in Michigan, offering comprehensive treatment and diagnosis services for cancer patients. This allows McLaren to offer the latest generation of advanced technology to fight cancers, but also to provide a comprehensive set of services that cancer patients need, all under one roof. The center’s advanced technology includes pencil-beam scanning capability, making it possible to offer intensity modulated proton therapy (IMPT). IMPT is a highly specialized proton therapy that delivers a precise dose of protons, often to constrained targets.
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch software is used by over 800 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved.
* Subject to regulatory clearance in some markets.
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
Björn Hårdemark, interim CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 709 564 217